Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.66 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.66 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464990 | 0.88 | MAPT (0.66) | MAPTKDM4EPOLBHTTMDM2 | |
| SCHEMBL549108 | 0.87 | MAPT (0.73) | MAPTHTTRXFP1PTGS1 | |
| SCHEMBL4474988 | 0.86 | PTGS1 (0.67) | MAPTKDM4EPOLBHTTMDM2 | |
| SCHEMBL4463935 | 0.81 | PTGS1 (0.89) | MAPTPOLBHTTRXFP1PTGS1 | |
| SCHEMBL11307930 | 0.79 | PTGS1 (0.76) | MAPTHTTNPC1RXFP1PTGS1 | |
| SCHEMBL5667231 | 0.79 | PTGS1 (0.67) | MAPTKDM4ERXFP1PTGS1 | |
| SCHEMBL22025008 | 0.79 | MAPT (0.64) | MAPTKDM4EPOLBHTTRXFP1 | |
| SCHEMBL13066016 | 0.78 | MAPT (0.55) | MAPTKDM4EHTTRXFP1PTGS1 | |
| SCHEMBL13066011 | 0.78 | HDAC3 (0.55) | MAPTKDM4EHTTPTGS1 | |
| SCHEMBL2193786 | 0.78 | PTGS1 (0.67) | MAPTKDM4EHTTRXFP1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | claimed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | claimed |
| EP-1919924-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-05-14 | — | — | EP | claimed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | claimed |
| EP-1899329-B1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-05 | — | — | EP | disclosed |
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| EP-1919924-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | AURKC, PTK2B, FRK | MAPT 1523/4885KDM4E 2272/4885POLB 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.